To evaluate the efficacy of sub-endometrial autologous stem cell implantation in women with severe degree of Asherman's Syndrome. (Efficacy is defined as resumption of menstruation). Prospective, Case series. Patients with Asherman's Syndrome (n=6) where other treatment options had failed; bone marrow aspiration was done from iliac crest under local anesthesia .Bone marrow (30 ml) was aspirated using bone marrow aspiration needle (Jamshidi, 11 G). It was collected in heparinised syringes. The Isolation of Mononuclear cells was done by Ficoll density separation method at Stem cell facility.Harvested stem cells were implanted in sub-endometrial zone as identified by transvaginal scan through trans-myometrial route using ovum pick up needle (Cook,17 G) under I.V.sedation.Post implantation patients were given oral Estradiol Valerate (Progynova, Schering manufacturer) 2mg thrice a day for six weeks followed by cyclic Estrogen & progesterone therapy for 3 months(Medroxy-progesterone acetate, Serum Institute of India LTD.) 10 mg once daily from day21- day27. Women were followed up at 3, 6 and 9 month intervals by trans-vaginal ultrasound for the endometrial thickness. Descriptive statistics and statistical analysis of study variables was carried out using STATA version 9.0. Changes in endometrial thickness values due to treatment was compared using ‘t’ –Paired test to see the significant increase in ET values at 3 months, 6 months and 9 months. Mean ±Standard deviation of ET values at 3 months (4.05±1.40), 6 months(5.46±1.36) and 9 months (5.48±1.14) were significantly (P<0.05) increased from pre treatment level (1.38±0.39). The mean (±SD) of MNC counts was 103.3 (±20.45) and ranged from 76 ×10 6 to 128×10 6. Similarly the mean (±SD) of CD34 was 203642 (±269274) and ranged between 10640 and 640090 with median value 58800. Haemopoitic stem cells implantation results in endometrial regeneration in Asherman Syndrome.